MEDEA Biopharma develops high-precision antimicrobials using bacteriophages to target and eliminate harmful bacteria, addressing the growing issue of antibiotic resistance. Their solutions are applicable across various industries, including animal health, aquaculture, and food safety, providing sustainable antibacterial options.
Funding
Funding not disclosed
MSFounders
Product
Problem
The overuse of broad-spectrum antibiotics has led to a rise in antibiotic-resistant bacteria, posing a significant threat to human and animal health. Current antibacterial solutions often lack precision, disrupting beneficial microbial communities and failing to address the root cause of infections.
Solution
MEDEA Biopharma develops targeted antimicrobial solutions using bacteriophages, naturally occurring viruses that selectively infect and eliminate specific bacteria. Their approach offers a sustainable alternative to traditional antibiotics by precisely targeting harmful bacteria while preserving beneficial microorganisms. MEDEA Biopharma identifies and validates bacterial targets, discovers effective bacteriophages, and develops scalable applications for various industries. This technology enables the creation of tailored antibacterial solutions that address the growing challenge of antibiotic resistance in a precise and environmentally conscious manner.
Target Audience
MEDEA Biopharma's primary customers include companies in the animal health, aquaculture, and food safety industries seeking sustainable and targeted antibacterial solutions.
Features
- High-precision targeting of harmful bacteria using specifically selected bacteriophages
- Sustainable antibacterial solutions that minimize disruption to beneficial microbial communities
- Scalable applications across diverse industries, including animal health, aquaculture, and food safety
- Identification and validation of bacterial targets for customized phage development
- Development of novel antimicrobial compounds based on bacteriophage technology